Chronic liver disease is a silent, global epidemic. But as metabolic conditions continue to rise, integrating digital diagnostics into routine blood work is unlocking the power of early, proactive intervention, shifting the healthcare paradigm from reactive treatment to lifelong prevention.

Liver disease is no longer a niche health issue. It is a growing public health challenge affecting an estimated 1.5 billion people worldwide and placing increasing pressure on healthcare systems.

Yet despite advances in our understanding of disease risk and progression, too many patients are still being diagnosed only after significant and often irreversible liver damage has already occurred.

The scale of the problem is difficult to ignore. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is estimated to affect around 38% of the global population.

In the UK alone, approximately one in four adults are believed to be living with the condition, making it the most common form of chronic liver disease.

This marks a significant shift in the liver disease landscape. Historically, liver disease was viewed primarily through the lens of alcohol-related harm. While alcohol remains an important contributor, today’s burden is increasingly driven by rising rates of obesity, type 2 diabetes and wider metabolic ill health.

As these conditions become more common, so too does the number of people at risk of developing progressive liver disease.

The consequences are already becoming visible. Between 2004 and 2022, MASLD diagnoses and advanced liver disease outcomes nearly tripled in England. Premature liver disease deaths have increased by 42% since 2001, reaching almost 11,000 deaths in 2023.

The economic burden is also substantial, with diagnosed MASLD estimated to cost between £2.3 billion and £4.2 billion in the UK alone.

Yet one of the greatest challenges is that liver disease often develops silently. Patients can feel entirely well while fibrosis advances over many years.

By the time symptoms emerge, the opportunity for earlier intervention may already have passed, allowing disease to progress towards cirrhosis, liver failure or hepatocellular carcinoma, the most common form of liver cancer and the third leading cause of cancer-related death worldwide.

This is the challenge at the heart of modern liver care. We know far more than ever before about who is at risk and how disease progresses.

But that knowledge has not always translated into consistently earlier diagnosis.
The question facing healthcare systems today is not simply how we manage advanced disease. It is what becomes possible when we identify risk sooner.

Our understanding of liver disease has evolved considerably over the last decade. Increasingly, liver health cannot be viewed in isolation from wider cardiometabolic health.

MASLD frequently coexists with obesity, type 2 diabetes, hypertension and cardiovascular disease. In many cases, these conditions are part of the same underlying metabolic picture.

This matters because it changes where we look for opportunities to identify patients at risk of liver disease, as they are no longer found exclusively within hepatology services.

They may be seen in primary care, diabetes clinics, cardiovascular pathways and weight-management programmes. Liver health therefore becomes relevant across a much broader section of healthcare than was once assumed.

At the same time, alcohol-related liver disease remains an important and potentially under-recognised contributor to overall burden.

Recent clinical studies utilising blood-based alcohol biomarkers reveal that alcohol-related cases are vastly under-reported by patients due to social stigma.

In reality, the true burden of these conditions is nearly twice as high as patient records suggest.

This means clinicians are often managing patient risk unaware of the dual metabolic and alcohol-related factors at play.

Taken together, these trends reinforce a central reality: there are likely to be more patients at risk than healthcare systems currently identify.

But they also point to a significant opportunity.

Risk factors are often visible long before symptoms develop. Clinical information already exists. Patients are frequently already present within healthcare pathways.
The challenge is connecting those dots in a consistent and scalable way.

If earlier diagnosis creates new opportunities for patients, the next question is how healthcare systems can make earlier identification a reality.

This is where risk stratification is attracting growing attention.
Every day, laboratories generate vast amounts of clinical information through routine testing. Within that data may be important indicators of liver disease risk.
Historically, however, translating those signals into actionable insight has not always been straightforward.

The challenge is not simply collecting more data. It is making better use of data that already exists.

Many healthcare systems continue to face growing demand, workforce pressures and finite resources. Any approach to earlier diagnosis must therefore be both scalable and practical.